# REFERENCES '

- 1.Groh, V. et al. (2001) Nature Immunol. 2:255.
- 2.Stephens, H. (2001) Trends Immunol. 22:378.
- 3.Bauer, S. et al. (1999) Science 285:727.
- 4.Groh, V. et al. (2002) Nature 419:734.
- 5. Steinle, A. et al. (2001) Immunogenetics 53:279.
- 6.Pende, D. et al. (2002) Cancer Res. 62:6178.

# Human PIGF Immunoassay

Catalog Number: SEKH-0296

For the quantitative determination of human PIGF concentrations in cell culture supernates, serum, and plasma.

For research use only. Not for use in diagnostic procedures.

Country | Company: China | Beijing Solarbio Science & Technology Co.,Ltd Address:NO.85A, Liandong U Valley, Tongzhou District, Beijing, P.R.China.

Tel: 86-10-56371241 Fax: 86-10-56371282 E-mail: service@solarbio.com

# **TABLE OF CONTENTS**

SECTION	PAGE
BACKGROUND	01
PRINCIPLE OF THE ASSAY	01
TECHNICAL HINTS AND LIMITATIONS	02
PRECAUTIONS	02
KIT COMPONENTS& STORAGE CONDITIONS	03
OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED	04
SPECIMEN COLLECTION & STORAGE	04
REAGENTS PREPARATION	04
ASSAY PROCEDURE	06
CALCULATION OF RESULTS	06
PERFORMANCE CHARACTERISTICS	08
REFERENCES	10

**LINEARITY:**To assess the linearity of the assay, three samples were spiked with high concentrations of PIGF in various matrices and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay.

# The linearity of the assay

Dilution ratio	Recovery(%)	Citrate plasma	Cell culture supernatants
1.2	Average% of Expected	97	88
1.2	Range (%)	92-108	80-97
1:4	Average% of Expected	100	91
1.4	Range (%)	97-113	85-102

#### Performance Characteristics

**SENSITIVITY:** The minimum detectable dose was 15.6 pg/mL. **SPECIFICITY:** This assay recognizes both natural and recombinant human PIGF. The factors listed below were prepared at 100ng/ml in Standard /sample Diluent and assayed for cross-reactivity and no significant cross-reactivity or interference was observed.

Factors assayed for cross-reactivity

Recombinant human	Recombinant mouse	Recombinant porcine
PDGF	PIGF-2	
VEGF		

**REPEATABILITY:** The coefficient of variation of both intra-assay and inter-assay were less than 10%.

**RECOVERY:** The recovery of PIGF spiked to three different levels in four samples throughout the range of the assay in various matrices was evaluated.

Sample Type	Average % of Expected Range(%)	Range(%)
Citrate plasma	93	85-101
Cell culture supernatants	98	90-111


#### BACKGROUND

PIGF (placenta growth factor) is a homodimeric growth factor that competes with VEGF for binding to VEGF R1/Flt-1. It therefore increases the availability of VEGF to bind to VEGF R2/KDR/Flk-1 and trigger angiogenesis. It can form heterodimers with some forms of VEGF and decrease the angiogenic effect of VEGF on VEGF R2. Circulating PIGF levels increase during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. PIGF induces monocyte activation and migration as well as production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis. PIGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension.

# PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for PIGF has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any PIGF present is captured by the coated antibody after incubation. Following extensive washing, a biotin-conjugate antibody specific for PIGF is added to detect the captured PIGF protein in sample. For signal development, horseradish peroxidase (HRP)-conjugatedStreptavidinis added, followed by tetramethyl-benzidine (TMB) reagent. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.

08 www.solarbio.com 400-968-6088 www.solarbio.com 400-968-6088 01



# TECHNICAL HINTS AND LIMITATIONS

- 1.This Solarbio ELISA should not be used beyond the expiration data on the kit label.
- 2.To avoid cross-contamination, use a fresh reagent reservoir and pipette tips for each step.
- 3.To ensure accurate results, some details, such as technique, plasticware and water sources should be emphasized.
- 4.A thorough and consistent wash technique is essential for proper assay performance.
- 5.A standard curve should be generated for each set of samples assayed.
- 6.It is recommended that all standards and samples be assayed in duplicate.
- 7.Avoid microbial contamination of reagents and buffers. Buffers containing protein should be made under aseptic conditions and be prepared fresh daily.
- 8. In order to ensure the accuracy of the results, the standard curve should be made every time.

## **PRECAUTIONS**


The Stop Solution suggested for use with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.

regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

5.This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

## Typical data using the PIGF ELISA

Standared(pg/ml)	OD.	OD.	Average	Corrected
0	0.048	0.039	0.043	
31.25	0.172	0.205	0.188	0.145
62.5	0.250	0.298	0.274	0.230
125	0.372	0.443	0.407	0.364
250	0.591	0.703	0.647	0.604
500	0.960	1.142	1.051	1.007
1000	1.563	1.859	1.711	1.667
2000	2.546	3.029	2.788	2.744



Representative standard curve for PIGF ELISA

07

#### ASSAY PROCEDURE

Prepare all reagents and standards as directed. Wash the plate 3 times before assay.

Ţ

Add 100µl standard or samples to each well, incubate 90 minutes, 37°C.

Aspirate and wash 4 times

Add 100µl working solution of Biotin-Conjugate anti-human PIGF antibody to each well, incubate 60 minutes, 37°C.

Aspirate and wash 4 times

Add 100  $\mu l$  working solution of Streptavidin-HRP to each well, incubate 30 minutes, 37  $^{\circ}\mathrm{C}$  .

Aspirate and wash 5 times

Add 100µl Substrate solution to each well, incubate 15 minutes, 37  $^{\circ}$ C. Protect from light.



Add 50µl Stop solution to each well. Read at 450nm within 30 minutes.

#### CALCULATION OF RESULTS

- 1. The standard curve is used to determine the amount of specimens.
- First, average the duplicate readings for each standard, control, and sample. All O.D. values are subtracted by the mean value of blank control before result interpretation.
- 3. Construct a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.
- 4.The data may be linearized by plotting the log of the PIGF concentrations versus the log of the O.D. and the best fit line can be determined by

# KIT COMPONENTS& STORAGE CONDITIONS

PART	SIZE	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Microwell Plate - antibody coated 96-well Microplate (8 wells ×12 strips)	1 plate	Return unused wells to the foil pouch containing the desiccant pack.Reseal along entire edge of the zip-seal.May be stored for up to 1 month at $2-8^{\circ}\text{C}^{**}$
Standard - lyophilized,2000 pg/ml upon reconstitution	2 vials	Store at -20°C** for six months
Concentrated Biotin-Conjugated antibody(100X) - 120 ul/vial	1 vial	Store at 2-8°C **for six months
Concentrated Streptavi- din-HRP solution(100X) - 120 ul/vial	1 vial	Store at 2-8°C **for six months
Standard /sample Diluent - 16 ml/vial	1 bottle	Store at 2-8°C **for six months
Biotin-Conjugate antibody Diluent - 16 ml/vial	1 bottle	Store at 2-8°C **for six months
Streptavidin-HRP Diluent - 16 ml/vial	1 bottle	Store at 2-8°C **for six months
Wash Buffer Concentrate (20x) - 30 ml/vial	1 bottle	Store at 2-8°C **for six months
Substrate Solution - 12 ml/vial	1 bottle	Store at 2-8°C **for six months
Stop Solution - 12 ml/vial	1 bottle	Store at 2-8°C **for six months
Plate Cover Seals	4 pieces	

<sup>\*\*</sup>Provided this is within the expiration date of the kit.

06 www.solarbio.com 400-968-6088 www.solarbio.com 400-968-6088 03

#### OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED

- 1. Microplate reader capable of measuring absorbance at 450 nm.
- 2. Pipettes and pipette tips.
- 3.Deionized or distilled water.
- 4. Squirt bottle, manifold dispenser, or automated microplate washer.
- 5.500 mL graduated cylinder.
- 6. Human PIGF controls (optional; available from Solarbio).

#### **SPECIMEN COLLECTION & STORAGE**

**Cell Culture Supernates** - Centrifuge cell culture media at 1000×g to remove debris. Assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles.

**Serum** - Use a serum separator tube (SST) and allow samples to clot for 2 hours at room temperature or overnight at 2-8  $^{\circ}$ C. Centrifuge at approximately for 15 minutes at 1000×g. Assay immediately or aliquot and store samples at  $\leq$  -20 $^{\circ}$ C. Avoid repeated freeze-thaw cycles.


**Plasma** - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at 1000×g within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles.

Note: It is recommended to conduct a pre-test before the formal experiment to determine the dilution ratio.

### REAGENTS PREPARATION \

- Temperature returning Bring all kit components and specimen to room temperature (20-25 C) before use.
- 2. Wash Buffer Dilute 30mL of Wash Buffer Concentrate with 570mL of deionized or distilled water to prepare 600mL of Wash Buffer. If crystals have formed in the concentrate Wash Buffer, warm to room temperature and mix gently until the crystals have completely dissolved.

- 3. Standard\Specimen Reconstitute the Standard with 1.0mL of Standard/Sample Diluent. This reconstitution produces a stock solution of 2000pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 500uL ofStandard/Sample Diluent into 1000pg/ml tube and the remaining tubes. Use the stock solution of 2000pg/mL to produce a 2-folddilution series (below). Mix each tube thoroughly and change pipette tips between each transfer. The 2000pg/mL standard serves as the high standard. The Standard/Sample Diluent serves as the zero standard (0 pg/mL).
  - \*If you do not run out of re-melting standard, store it at -20° $\rm C$ . Diluted standard shall not be reused.
- 4. Working solution of Biotin-Conjugate anti-human PIGF antibody: Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with the Biotin-Conjugate antibody Diluent in a clean plastic tube.
  - \*The working solution should be used within one day after dilution.
- Working solution of Streptavidin-HRP: Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with the Streptavidin-HRP Diluent in a clean plastic tube.
  - \*The working solution should be used within one day after dilution.



Preparation of PIGF standard dilutions

04